📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-05 14:35
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Link Pharma Chem Q1 Results: PAT at ₹0.32 Cr, Revenue Grows 12% YoY to ₹8.77 Cr
Link Pharma Chem reported a recovery in Q1 FY27, turning profitable with a PAT of ₹0.32 Cr compared to a loss of ₹0.41 Cr in the previous quarter (Mar 2026). Revenue from operations grew 12.2% YoY to ₹8.77 Cr and 33% sequentially. While the turnaround is positive, operating margins remain thin, and nearly 46% of the Profit Before Tax (₹0.18 Cr out of ₹0.39 Cr) was derived from fair value gains on financial assets rather than core operations. The company remains a micro-cap with a market capitalization of only ₹11 Cr.
Confidence: HIGH
What changedThe company has returned to profitability in Q1 FY27 after reporting a loss in the final quarter of FY26, supported by a 33% sequential increase in revenue.
Why it mattersFor a micro-cap company with a ₹11 Cr market cap, small absolute changes in profit (₹0.3-0.4 Cr) lead to significant swings in EPS and valuation, making quarterly consistency critical for investor confidence.
Revenue (Q1 FY27): ₹8.77 CrPAT (Q1 FY27): ₹0.32 CrRevenue vs TTM Revenue: 32.5%Fair Value Gain on Financial Assets: ₹0.18 CrYoY Revenue Growth: 12.2%
📅 Short termThe stock may see positive sentiment due to the turnaround from a loss-making quarter and the sequential revenue jump.
📈 Long termLimited structural change; the company needs to significantly scale its operations beyond the current ₹27-30 Cr annual revenue range to improve its low ROCE of 3.5%.
⚠ Risk flags
- High dependence on non-operating fair value gains for bottom-line growth
- Thin operating margins sensitive to raw material costs
- Micro-cap liquidity risk
Key Highlights
Revenue from operations increased to ₹8.77 Cr from ₹7.81 Cr in the same quarter last year.
Net Profit stood at ₹0.32 Cr, recovering from a loss of ₹0.41 Cr in the March 2026 quarter.
Fair value gains on financial assets contributed ₹0.18 Cr to the total income of ₹9.12 Cr.
Cost of materials consumed rose to ₹3.78 Cr compared to ₹2.70 Cr in the year-ago period.
Earnings Per Share (EPS) improved to ₹0.72 from a negative ₹0.92 in the preceding quarter.
👀 What to Watch
Investors should monitor if the company can sustain a quarterly revenue run-rate above ₹9 Cr to maintain profitability, as the current margins are highly sensitive to raw material price fluctuations.
Link Pharma Chem Q1 Results: Revenue Grows 12% YoY to ₹8.77 Cr, Returns to Profitability
Link Pharma Chem reported a recovery in Q1 FY27 (ending June 2026) with revenue of ₹8.77 Cr, up 12.2% from ₹7.81 Cr in the same quarter last year. The company posted a Net Profit of ₹0.32 Cr, a significant turnaround from the ₹0.41 Cr loss recorded in the preceding quarter (March 2026). However, profitability remains fragile as Other Income of ₹0.35 Cr accounted for nearly 90% of the Profit Before Tax (₹0.39 Cr). With a micro-cap valuation of ₹11 Cr and debt of ₹7 Cr, the company's financial stability remains closely tied to maintaining these quarterly revenue levels.
Confidence: HIGH
What changedThe company has transitioned from a loss-making quarter in March 2026 back to a profitable state in June 2026, alongside a modest year-on-year revenue increase.
Why it mattersFor a micro-cap company with a market capitalization of only ₹11 Cr, consistent quarterly profitability is essential to manage its ₹7 Cr debt and improve its low ROCE of 3.5%.
Revenue (Q1 FY27): ₹8.77 CrNet Profit (Q1 FY27): ₹0.32 CrQ1 Revenue vs TTM Revenue: 32.4%Other Income: ₹0.35 CrDebt to Equity: 0.57
📅 Short termThe stock may see positive sentiment in the short term due to the sequential turnaround from a loss to a profit and double-digit YoY revenue growth.
📈 Long termLong-term prospects remain limited unless the company can significantly scale its operations beyond the current ₹27 Cr annual revenue run rate and improve core operating efficiency.
⚠ Risk flags
- High dependence on non-operating income for profitability
- Micro-cap liquidity risk
- Thin operating margins (OPM 5.2%)
Key Highlights
Revenue from operations increased to ₹8.77 Cr from ₹7.81 Cr in the year-ago period.
Net Profit reached ₹0.32 Cr compared to a loss of ₹0.41 Cr in the previous quarter.
Other Income of ₹0.35 Cr included a fair value gain of ₹0.18 Cr on financial assets.
Cost of materials consumed stood at ₹3.78 Cr, approximately 43% of total revenue.
Finance costs rose to ₹0.14 Cr, up from ₹0.10 Cr in the corresponding quarter last year.
👀 What to Watch
Watch for the sustainability of operating margins in upcoming quarters to see if the company can generate profits from core operations without relying on fair value gains in 'Other Income'.
